Company Performance Metrics
Curonz is a clinical stage biotechnology company with a drug portfolio covering the peptide family, Neural Regeneration Peptides (NRPs), which were discovered by Curonz's founding Director, Dr Frank Sieg and where precursor compounds to our clinical molecule NRP2945 were first patented back in 2001. We currently have offices in Delaware, NZ
and Australia.
We have completed Clinical Phase I in Australia for our lead drug candidate NRP2945 with 49 healthy volunteers. Currently, we are studing NRP2945 in a small Phase II proof of concept study in adults with typical absence epilepsy which is due to finish mid 2019. We are looking for investment to conduct a clinical phase 2 study in Temporal Lobe Epilepsy as well as has plans for a clinical phase II study in Lennox-Gastaut Syndrome children. NRP2945 exerts its activity via agonism of a novel CXCR4 receptor complex in an ultra-potent manner with no off-target effects.
Curonz aims to licensing the platform of compounds or reach other commercial arrangements to provide a clear pathway forward to bring this promising therapeutic treatment as quickly as possible to patients.
